Akili(AKLI)
Search documents
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan
Businesswire· 2024-02-27 07:00
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. (Nasdaq: AKLI) announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of Akili’s AKL-T01 (m ...
Why Is Akili (AKLI) Stock Up 110% Today?
InvestorPlace· 2024-02-26 18:51
A little known penny stock is turning heads on Wall Street today as it surges to impressive heights. Digital health company Akili Interactive Labs (NASDAQ:AKLI) stock is soaring after reporting a positive trial update. Shionogi (OTCMKTS:SGIOY), Akili’s Japanese partner, has confirmed that it has submitted SDT-001 (sold as EndeavorRx in the U.S.), a digital therapeutic producer by Akili for marketing approval with Japan’s Ministry of Health, Labor, and Welfare. Described as “the world’s first prescription di ...
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in Japan
Businesswire· 2024-02-26 13:47
BOSTON--(BUSINESS WIRE)--Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of Akili’s AKL-T01 (marketed as EndeavorRx® in the United States), which has previously been authorized by the U.S. Food and Drug Administration (FDA) as the world's first prescription digital ther ...
Akili(AKLI) - 2023 Q3 - Earnings Call Transcript
2023-11-12 13:03
Akili, Inc. (NASDAQ:AKLI) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Caty Reid - Vice President Marketing & Communications Matt Franklin - President & Chief Operating Officer Scott Kollins - Chief Medical Officer Santosh Shanbhag - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Charles Rhyee - TD Cowen Rahul Rakhit - LifeSci Capital Operator Good afternoon, ladies and gentlemen and welcome to the Akili Interactive Labs Third Quarte ...
Akili(AKLI) - 2023 Q3 - Quarterly Report
2023-11-08 16:00
tROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-40558 Akili, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...
Akili(AKLI) - 2023 Q2 - Earnings Call Transcript
2023-08-13 13:27
Akili, Inc. (NASDAQ:AKLI) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Julie DiCarlo - Senior Vice President, Communications Eddie Martucci - Chief Executive Officer Matt Franklin - President and Chief Operating Officer Santosh Shanbhag - Chief Financial Officer Scott Kollins - Chief Medical Officer Conference Call Participants Judah Frommer - Credit Suisse Gus Paul - Morgan Stanley Rahul Rakhit - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome ...
Akili(AKLI) - 2023 Q2 - Quarterly Report
2023-08-09 16:00
tROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 u FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-40558 w Akili, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 9 ...
Akili(AKLI) - 2023 Q1 - Quarterly Report
2023-05-11 16:00
tROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 u FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-40558 w Akili, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware ...
Akili(AKLI) - 2022 Q4 - Earnings Call Transcript
2023-03-10 20:36
Akili, Inc. (NASDAQ:AKLI) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Julie DiCarlo - Senior Vice President of Communications Eddie Martucci - Co-Founder, CEO & Director Matthew Franklin - President & COO Scott Kollins - Chief Medical Officer Santosh Shanbhag - CFO & Treasurer Conference Call Participants Nicholas Japhet - Credit Suisse Michael Cherny - BofA Securities Rahul Rakhit - LifeSci Capital Vikram Purohit - Morgan Stanley Marie Thibault - BTIG Operator Greetings ...
Akili(AKLI) - 2022 Q4 - Annual Report
2023-03-08 16:00
pic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________________ TO ____________________ Commission File Number 001-40558 Akili, Inc. (Exact name of Registrant as specified in its Charter) Delaware 98-15 ...